Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Almudena Zapatero

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2010
Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatmentFrancesc Casas, Josep María Borràs, Ferran Ferrer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2015
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapyJose López-Torrecilla, Anna Boladeras, María Angeles Cabeza, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 TrialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2021
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trialAlmudena Zapatero, Ana Álvarez, Araceli Guerrero, et al.
Frontiers in Immunology|December 5, 2024
Immunome profiling in prostate cancer: a guide for cliniciansLuis San-Jose Manso, Arantzazu Alfranca, Ignacio Moreno-Pérez, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|November 10, 2015
SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional studyPilar Ma Samper Ots, Julia Luisa Muñoz García, Yesika Ríos Kavadoy, et al.
The Lancet. Oncology|February 24, 2015
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 18, 2026
Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohortDaniela Greto, Van Hemelrijck Mieke, Felix Oppong, et al.
The Lancet. Oncology|April 15, 2022
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized TrialsLucia Kwak, Praful Ravi, John G Armstrong, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2010
Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatmentFrancesc Casas, Josep María Borràs, Ferran Ferrer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2015
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapyJose López-Torrecilla, Anna Boladeras, María Angeles Cabeza, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 TrialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 8, 2021
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trialAlmudena Zapatero, Ana Álvarez, Araceli Guerrero, et al.
Frontiers in Immunology|December 5, 2024
Immunome profiling in prostate cancer: a guide for cliniciansLuis San-Jose Manso, Arantzazu Alfranca, Ignacio Moreno-Pérez, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|November 10, 2015
SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional studyPilar Ma Samper Ots, Julia Luisa Muñoz García, Yesika Ríos Kavadoy, et al.
The Lancet. Oncology|February 24, 2015
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 18, 2026
Short-term quality of life after metastases-directed SBRT: Results of the ESTRO & EORTC OligoCare cohortDaniela Greto, Van Hemelrijck Mieke, Felix Oppong, et al.
The Lancet. Oncology|April 15, 2022
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trialAlmudena Zapatero, Araceli Guerrero, Xavier Maldonado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2024
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized TrialsLucia Kwak, Praful Ravi, John G Armstrong, et al.
Pageof 7